Passive immunotherapeutics are important in post exposure prophylaxis and treatment of infectious diseases. Reagents for passive immunotherapy include convalescent sera and monoclonal antibodies (mAb). Murine, humanized and fully human mAb (fhmAb) share advantages with respect to defined specificity, and enhanced safety profiles. However, only fhmAb possess native effector functions and eliminate risk of immune responses to nonhuman components that have the potential to reduce efficacy and/or cause autoimmune disease. FhmAb that neutralize Rift Valley fever virus (RVFV), Nipah/Hendra virus (NiV/HeV), and West Nile virus (WNV) were created using a fully human fusion partner cell line (MFP-2) and PEL from patients after natural infection (NiV and WNV) or vaccination (RVFV).
In Aim 1 of this project we will characterize these fhmAb in vivo. PBL from immune donors can difficult to obtain, particularly early in the course of an outbreak;thus, alternative strategies are needed whereby fhmAbs with optimized reactivity can be generated using synthetic reagents and in vitro maturation methods. Toward this end we will test (in Aims 2 and 3) the utility of a genetically engineered Veloclmmune? mouse for producing fhmAb from recombinant antigens representing NiV and Chikungunya virus (CHIKV). Functionality of Veloclmmune-drived mAb to NiV will be compared to that of the mAb generated with MFP-2. Furthermore, (Aim 4) we will apply two complementary methods for in vitro optimization of mAb reactivity: a yeast dual-display system that allows for in vitro mutation of cloned sequences followed by high throughput selection of reactive variants in a yeast system, and somatic hypermutation using the Ramos cell and/or activation induced cytidine deaminase (AID) systems.
Specific Aims are: (1) Characterize biological efficacy of existing fhmAb to RVFV, NiV/HeV and WNV;( 2) Generate fhmAb from protective Veloclmmune mAb to NiV and CHIKV;(3) Characterize Veloclmmune immune response and functionality of generated mAb;(4) Use recombinant genetics, mutagenesis, and somatic hypermutation to optimize mAb reactivity.

Public Health Relevance

Passive immunotherapy has an established track record in post exposure prophylaxis and treatment of infectious diseases and will continue to be a significant primary or complementary line of defense. With this project we will generate safe and specific fully human monoclonal antibody (fhmAb) therapeutics for Category A-C agents and establish a universal platform for efficiently generating these tools from entirely synthetic source materials, enabling a swift response to newly identified disease threats.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057158-09
Application #
8376724
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
9
Fiscal Year
2012
Total Cost
$402,448
Indirect Cost
$73,698
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Charles, Jermilia; Firth, Andrew E; Loroño-Pino, Maria A et al. (2016) Merida virus, a putative novel rhabdovirus discovered in Culex and Ochlerotatus spp. mosquitoes in the Yucatan Peninsula of Mexico. J Gen Virol 97:977-87
Pham, Alissa M; Santa Maria, Felicia Gilfoy; Lahiri, Tanaya et al. (2016) PKR Transduces MDA5-Dependent Signals for Type I IFN Induction. PLoS Pathog 12:e1005489
Song, Jeongmin; Wilhelm, Cara L; Wangdi, Tamding et al. (2016) Absence of TLR11 in Mice Does Not Confer Susceptibility to Salmonella Typhi. Cell 164:827-8
Li, Melody M H; Bozzacco, Leonia; Hoffmann, Hans-Heinrich et al. (2016) Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J Exp Med 213:2931-2947
Moser, Lindsey A; Lim, Pei-Yin; Styer, Linda M et al. (2016) Parameters of Mosquito-Enhanced West Nile Virus Infection. J Virol 90:292-9
Basu, Debaleena; Kahn, Jennifer N; Li, Xiao-Ping et al. (2016) Conserved Arginines at the P-Protein Stalk Binding Site and the Active Site Are Critical for Ribosome Interactions of Shiga Toxins but Do Not Contribute to Differences in the Affinity of the A1 Subunits for the Ribosome. Infect Immun 84:3290-3301
Steyer, Andrej; Jevšnik, Monika; Petrovec, Miroslav et al. (2016) Narrowing of the Diagnostic Gap of Acute Gastroenteritis in Children 0-6 Years of Age Using a Combination of Classical and Molecular Techniques, Delivers Challenges in Syndromic Approach Diagnostics. Pediatr Infect Dis J 35:e262-70
Uhde, Melanie; Ajamian, Mary; Li, Xueting et al. (2016) Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease. Clin Infect Dis 63:1399-1404
Jacek, Elzbieta; Tang, Kevin S; Komorowski, Lars et al. (2016) Epitope-Specific Evolution of Human B Cell Responses to Borrelia burgdorferi VlsE Protein from Early to Late Stages of Lyme Disease. J Immunol 196:1036-43
Aguilar, Jorge L; Varshney, Avanish K; Pechuan, Ximo et al. (2016) Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence :1-10

Showing the most recent 10 out of 643 publications